Tag: Palforzia (AR101)

Peanut M&M's

Study Determines What Patients Prefer for Maintenance After Completing OIT with...

Patients chose from continuing with Palforzia or switching to a common food.
AIM_Palforzia_SnackSafely_Article_Holiday_imagesFamily

This Holiday Season, See the Potential Impact that Peanut Allergy Treatment...

Did you know there’s a treatment option in addition to avoidance alone?

Notebooks, check. Backpack, check. Peanut allergy treatment, check. (Sponsored)

What if you could give your child a treatment option, in addition to practicing a strict peanut-free diet?
Allergens

USF Begins Recruitment for OIT Study Addressing 15 Food Allergies at...

Therapy will treat allergies to peanuts, almonds, cashew, hazelnuts, pecans, pistachios, walnuts, codfish, salmon, shrimp, sesame seed, soy, wheat, milk and eggs simultaneously.
Palforzia Capsules with Logo

Study: More Than 80% of Patients Could Tolerate 2000mg of Peanuts...

Safety and efficacy increased over time with treatment.
Palforzia Ad

How the First FDA-Approved Therapy for Peanut Allergy is Helping Families (Sponsored)

What is PALFORZIA?  PALFORZIA is a treatment for people who are allergic to peanuts. PALFORZIA can help reduce the severity of allergic reactions, including anaphylaxis,...
Palforzia Capsules with Logo

Aimmune Presents New Clinical Data From Patients Treated With PALFORZIA® for...

Majority of patients experienced low rates of adverse events which declined in frequency and severity with continued treatment.
Handful of Peanuts

Peanut Allergy More Common in Adults Than Children, Many Report First...

Peanut allergy affects at least 4.5 million adults in the US.
Nestle Acquires Aimmune

Nestlé to Acquire Aimmune Therapeutics

Nestlé Health Science and Aimmune to create a global leader in food allergy prevention and treatment.
Palforzia Capsules with Logo

Results of Aimmune’s Pivotal Phase 3 European Trial of PALFORZIA® Published...

Peanut-allergic patients treated with Palforzia showed desensitization to peanut protein with a predictable safety profile at nine months